SBC Medical vs Starling Oncology
SBC and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SBC and STLN compare
Starling Oncology is the larger company, worth 1.2 times as much as SBC Medical ($666M against $543M).
Starling Oncology grew revenue faster over the last twelve months (38.4% versus −6.9% for SBC Medical).
SBC Medical keeps more of each dollar of sales as profit, with a net margin of 28.0% compared with −6.2% at Starling Oncology.
SBC Medical scores higher on the StockData Score (12 against 6 for Starling Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SBC | STLN |
|---|---|---|
| Size and price | ||
| Market cap | $543M | $666M |
| Share price | $5.28 | $6.53 |
| Change, 1 year | 56.1% | 38.9% |
| Change, 5 years | – | −34.6% |
| Beta (5Y) | 0.42 | 1.60 |
| Employees | 863 | 641 |
| StockData Score | ||
| Total score | 12 (better) | 6 |
| Valuation score | 4 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 11.2× | – |
| P/S | 3.1× | 1.1× (better) |
| P/B | 2.1× | – |
| EV/EBITDA | 5.5× | – |
| P/FCF | 8.8× | – |
| FCF yield | 11.4% (better) | −0.49% |
| Fair value | $8.42 | – |
| Margin of safety | 37.3% | – |
| Growth | ||
| Revenue growth (TTM) | −6.9% | 38.4% (better) |
| Revenue growth, 5Y average | – | 21.8% |
| Net income growth (TTM) | 47.1% | – |
| EPS growth (TTM) | 46.9% | – |
| Profitability | ||
| Gross margin | 71.9% | – |
| Operating margin | 37.3% (better) | −4.4% |
| Net margin | 28.0% (better) | −6.2% |
| FCF margin | 35.3% (better) | −0.56% |
| Return on equity | 19.3% | – |
| Return on invested capital | 50.7% (better) | −83.1% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | −2.69 | – |
| Interest coverage | 195× (better) | −3.4× |
| Current ratio | 3.31 (better) | 1.36 |
| Altman Z-score | 4.97 (better) | 2.78 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 8.3% | 43.4% |
| Held by insiders | 82.0% | 56.6% |
| Insider net buying, 12 months | −$20.1M | −$122K (better) |
Go deeper
- SBC stock overview
- SBC income statement
- SBC valuation and score
- STLN stock overview
- STLN income statement
- STLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.